---
schema_version: "secwatch.filing_event.v1"
accession: "0001171843-23-003807"
form_type: "8-K"
ticker: "ABUS"
cik: "0001447028"
company_name: "Arbutus Biopharma Corp"
filed_at: "2023-06-07T23:59:59+00:00"
generated_at: "2026-06-14T05:43:33.578274+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.35
calibrated_materiality_score: 0.35
confidence: "high"
source: SEC EDGAR
---

# Arbutus to present AB-729 and AB-836 data at EASL Congress 2023

## Summary
- AB-729 + IFN in virally suppressed chronic HBV: well tolerated, mean HBsAg decline >1.6 log10 after 24 weeks.
- 88% of subjects achieved HBsAg <100 IU/mL; 2 subjects reached HBsAg <LLOQ during IFN treatment.
- AB-836 capsid inhibitor: no viral breakthrough or enrichment of resistant variants after 28 days across 48 subjects.
- Multiple core protein variants observed at higher frequencies, suggesting viral plasticity at those sites.

## SEC filing metadata
- accession: 0001171843-23-003807
- form_type: 8-K
- ticker: ABUS
- cik: 0001447028
- company_name: Arbutus Biopharma Corp
- filed_at: 2023-06-07T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.35
- calibrated_materiality_score: 0.35
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1447028/000117184323003807/0001171843-23-003807-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1447028/000117184323003807/f8k_060523.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001171843-23-003807
- JSON: https://secwatch.observer/filing/0001171843-23-003807.json
- Plain text: https://secwatch.observer/filing/0001171843-23-003807.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.